Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia-Reference-Cited by-同舟云学术

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

Published:2015-05-14 Issue:10 Volume:29 Page:1981-1992
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Khalife J,Radomska H S,Santhanam R,Huang X,Neviani P,Saultz J,Wang H,Wu Y-Z,Alachkar H,Anghelina M,Dorrance A,Curfman J,Bloomfield C D,Medeiros B C,Perrotti D,Lee L J,Lee R J,Caligiuri M A,Pichiorri F,Croce C M,Garzon R,Guzman M L,Mendler J H,Marcucci G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015106.pdf

Reference54 articles.

1. Burnett A, Wetzler M, Löwenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487–494.

2. Faraoni I, Antonetti FR, Cardone J, Bonmassar E . miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792: 497–505.

3. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869–17879.

4. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086–2093.

5. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 3622–3626.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein neddylation and its role in health and diseases;Signal Transduction and Targeted Therapy;2024-04-05

2. Anesthesia-mediated neuroinflammatory sequelae in post operative cognitive dysfunction: mechanisms and therapeutic implications;Frontiers in Anesthesiology;2024-02-27

3. A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis;Therapeutic Advances in Hematology;2024-01

4. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways;Acta Haematologica;2023-11-03

5. MicroRNA-155 and cancer metastasis: Regulation of invasion, migration, and epithelial-to-mesenchymal transition;Pathology - Research and Practice;2023-10